OTCMKTS:RNLXD Renalytix (RNLXD) Stock Price, News & Analysis $1.29 0.00 (0.00%) As of 05/28/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Renalytix Stock (OTCMKTS:RNLXD) Get Renalytix alerts:Sign Up Key Stats Today's Range$1.24▼$1.2950-Day Range$1.10▼$1.3652-Week Range$3.13▼$8.09Volume16,853 shsAverage Volume2,432 shsMarket Capitalization$11.27 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York. Read More Receive RNLXD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RNLXD Stock News HeadlinesRenalytix Plc (RNLXY)December 27, 2025 | finance.yahoo.comRenalytix PLC ADRDecember 23, 2025 | barrons.comBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.July 6 at 1:00 AM | Chaikin Analytics (Ad)Renalytix Adjusts Share Capital Amid Fundraising ShortfallNovember 6, 2024 | markets.businessinsider.comRenalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond USJuly 11, 2024 | globenewswire.comRenalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting DeterminationJune 27, 2024 | globenewswire.comMedicare Issues Final Coverage Determination for kidneyintelX.dkdJune 14, 2024 | globenewswire.comRNLX Stock Earnings: Renalytix Misses EPS, Misses Revenue for Q3 2024May 15, 2024 | investorplace.comSee More Headlines RNLXD Stock Analysis - Frequently Asked Questions How have RNLXD shares performed this year? Renalytix's stock was trading at $3.62 at the beginning of the year. Since then, RNLXD shares have decreased by 64.4% and is now trading at $1.29. How were Renalytix's earnings last quarter? Renalytix Plc (OTCMKTS:RNLXD) issued its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.11) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.11). The firm earned $0.46 million during the quarter, compared to the consensus estimate of $0.70 million. How do I buy shares of Renalytix? Shares of RNLXD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/14/2023Today7/06/2026Fiscal Year End6/30/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorComputer and Technology Industry Medical laboratories Sub-IndustryHealthcare Current SymbolOTCMKTS:RNLXD CIK1811115 Webwww.renalytixai.com Phone44-20-3139-2910FaxN/AEmployees100Year Founded2018Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.21 Quick Ratio1.17 Sales & Book Value Annual Sales$3 million Price / Sales3.76 Cash FlowN/A Price / Cash FlowN/A Book Value($1.06) per share Price / Book-1.22Miscellaneous Outstanding Shares8,740,000Free Float7,822,000Market Cap$11.27 million OptionableOptionable Beta2.63 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (OTCMKTS:RNLXD) was last updated on 7/6/2026 by MarketBeat.com Staff. From Our PartnersThree companies about to leapfrog Nvidia [And transform the entire industry]The government just committed $200 billion to building computer chips on American soil - one of the largest te...Eagle Publishing | SponsoredAmazon, Google, Meta, and Microsoft just committed $700 billionAmazon, Google, Meta, and Microsoft have committed $700 billion this year alone to AI infrastructure - more th...True Market Insiders | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renalytix Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Renalytix With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
